Date:	2021.06.03	
Your Name:	Lipeng Luan	
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma	_
Manuscript number	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ü	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China (GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03
Your Name:	Feng Lu
Manuscript Title:_	The predictive value of RNA binding proteins in colon adenocarcinoma
Manuscript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
		Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_ √None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√ None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	,	
6	Payment for expert	√None	
	testimony		
_			
7	Support for attending meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	/	
11	Stock or stock options	√None	
12	Possint of aguinment	/ Name	
12	Receipt of equipment, materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China (GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03
Your Name:	Xiaochuan Wang
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma
Manuscript numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from	_ √None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ü	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Yunliang Wang	
Manuscript Title:	_The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from	_ √None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ū	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Wei Wang	
Manuscript Title:	_The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript number	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_ √None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ū	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Yong Yang	_
Manuscript Title:	_The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript number	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Funding Funding	National Science Foundation of Jiangsu Province of China (BK20191172) The Key Laboratory of Clinical Pharmacy of Jiangsu
	medical writing, article processing charges, etc.) No time limit for this item.	Funding	Province of China (XZSYSKF2020027) The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) The Gusu Medical Key Talent of Suzhou City of China
		Time frame: past	(GSWS2020005)
2	Grants or contracts from any entity (if not indicated in item #1 above).	_ √None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ū	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Guoliang Chen	
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√ None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	,	
6	Payment for expert	√None	
	testimony		
_			
7	Support for attending meetings and/or travel		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data	√None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	/	
11	Stock or stock options	√None	
12	Possint of aguinment	/ Name	
12	Receipt of equipment, materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China (GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Huihui Yao	
Manuscript Title:	_The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript number	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ü	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03
Your Name:	Xinyu Shi
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma
Manuscript numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ü	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	ğ ,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Zihan Yuan	
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from	_ √None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ū	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	ğ ,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Guoqiang Zhou	
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript number (if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	√None	
	in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ū	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	ğ ,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03	
Your Name:	Haitao Zhang	
Manuscript Title:	_The predictive value of RNA binding proteins in colon adenocarcinoma	
Manuscript number	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)
	provision of study materials, medical writing, article	Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)
	processing charges, etc.) No time limit for this item.	Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)
		Time frame: past	36 months
2	Grants or contracts from	_ √None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
Ü	testimony		
	·		
7	Support for attending meetings and/or travel	√None	
	ğ ,		
8	Patents planned, issued or	√None	
	pending		
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement:

Date:	2021.06.03				
Your Name:	Songbing He				
Manuscript Title:	The predictive value of RNA binding proteins in colon adenocarcinoma				
Manuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed)		
Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding	National Science Foundation of Jiangsu Province of China (BK20191172)	
		Funding	The Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027)	
		Funding	The Science and Technology Development Plan of Suzhou City of China (SYS2019007)	
		Funding	Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007)	
		Funding	The Gusu Medical Key Talent of Suzhou City of China (GSWS2020005)	
Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated	_ √None		
	in item #1 above).			
3	Royalties or licenses	√None		
4	Consulting fees	√None		

	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	√ None	
	testimony		
	·		
	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or pending	√None	
9	Participation on a Data Safety Monitoring Board or	√None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
	other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,	_ √None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
_	Other financial or non-	√None	
	financial interests		

The author reports that this work was supported by the National Science Foundation of Jiangsu Province of China (BK20191172), the Key Laboratory of Clinical Pharmacy of Jiangsu Province of China (XZSYSKF2020027), the Science and Technology Development Plan of Suzhou City of China (SYS2019007), Project of New Pharmaceutics and Medical Apparatuses of Suzhou City of China (SLJ2021007) and the Gusu Medical Key Talent of Suzhou City of China .(GSWS2020005).

Please place an "X" next to the following statement to indicate your agreement: